Payment overview · 2025
General Payments
$55.41
2 reported records · 2 companies
Healthcare provider profile · identity verified
Thomas Jimenez, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MANATI, PR · NPI 1639287121
Verified facts
What the public records show
CMS Open Payments records show Thomas Jimenez, M.D. received $55.41 in general payments during 2025 across 2 reported records.
PBG PUERTO RICO LLC accounted for 51.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Paxlovid.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 147 records involving 126 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $28.33 | 51.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $27.08 | 48.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $55.41 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PBG PUERTO RICO LLC | $55.41 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PBG PUERTO RICO LLC | $28.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 88 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 11 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 30 |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 30 |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 147 supporting records · 126 recipient NPIs · example record 1228798592 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 613 | 209 |
| Famotidine | Famotidine | 387 | 136 |
| Gabapentin | Gabapentin | 370 | 118 |
| Losartan Potassium | Losartan Potassium | 366 | 126 |
| Synthroid | Levothyroxine Sodium | 330 | 92 |
| Metformin Hcl | Metformin Hcl | 296 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 296 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 251 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 171 | 55 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 170 | 37 |
| Simvastatin | Simvastatin | 168 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 54 |
| Trazodone Hcl | Trazodone Hcl | 148 | 57 |
| Candesartan Cilexetil | Candesartan Cilexetil | 147 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 53 |
| Glimepiride | Glimepiride | 119 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 38 |
| Irbesartan | Irbesartan | 97 | 37 |
| Lisinopril | Lisinopril | 91 | 33 |
| Eliquis | Apixaban | 88 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 34 |
| Finasteride | Finasteride | 80 | 25 |
| Tradjenta | Linagliptin | 80 | 25 |
| Enalapril Maleate | Enalapril Maleate | 79 | 22 |
| Omeprazole | Omeprazole | 79 | 34 |
| Jardiance | Empagliflozin | 77 | 17 |
| Montelukast Sodium | Montelukast Sodium | 77 | 30 |
| Carvedilol | Carvedilol | 74 | 26 |
| Humalog | Insulin Lispro | 73 | 20 |
| Clotrimazole | Clotrimazole | 55 | 38 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 55 | 32 |
| Donepezil Hcl | Donepezil Hcl | 55 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 23 |
| Alendronate Sodium | Alendronate Sodium | 53 | 18 |
| Prednisone | Prednisone | 53 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 17 |
| Sucralfate | Sucralfate | 49 | 19 |
| Farxiga | Dapagliflozin Propanediol | 47 | 13 |
| Xarelto | Rivaroxaban | 47 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 15 |
| Glipizide | Glipizide | 41 | 14 |
| Latanoprost | Latanoprost | 41 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 39 | 12 |
| Sertraline Hcl | Sertraline Hcl | 39 | 11 |
| Buspirone Hcl | Buspirone Hcl | 38 | 12 |
| Ezetimibe | Ezetimibe | 38 | 16 |
| Clonazepam | Clonazepam | 37 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 27 |
| Ciclopirox | Ciclopirox | 32 | 21 |
| Furosemide | Furosemide | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | 11 |
| Methylprednisolone | Methylprednisolone | 31 | 27 |
| Spironolactone | Spironolactone | 31 | 11 |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | 15 |
| Baclofen | Baclofen | 28 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 28 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 27 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Pentoxifylline | Pentoxifylline | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 22 |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 18 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | 11 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 19 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 19 | 15 |
| Allopurinol | Allopurinol | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 18 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 18 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 17 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | 13 |
| Glipizide Er | Glipizide | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Desloratadine | Desloratadine | 14 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 13 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Insulin Glargine | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $55.41 · 2 records | PBG PUERTO RICO LLC | ELIQUIS, PAXLOVID | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error